{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:10:27Z","timestamp":1761513027775},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2011,9,20]],"date-time":"2011-09-20T00:00:00Z","timestamp":1316476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00432-011-1056-3","type":"journal-article","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T18:50:15Z","timestamp":1316458215000},"page":"1729-1738","source":"Crossref","is-referenced-by-count":13,"title":["BCG response prediction with cytokine gene variants and bladder cancer: where we are?"],"prefix":"10.1007","volume":"137","author":[{"given":"Dinesh Kumar","family":"Ahirwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parmeet Kaur","family":"Manchanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama Devi","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemant K.","family":"Bid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,20]]},"reference":[{"issue":"2","key":"1056_CR1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/08923970903300151","volume":"32","author":"A Agarwal","year":"2010","unstructured":"Agarwal A, Agrawal U, Verma S, Mohanty NK, Saxena S (2010) Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacol Immunotoxicol 32(2):348\u2013356","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"1056_CR2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s00262-005-0045-2","volume":"55","author":"A Agarwal","year":"2006","unstructured":"Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S (2006) Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 55:734\u2013743","journal-title":"Cancer Immunol Immunother"},{"key":"1056_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2008.02.015","volume":"184","author":"D Ahirwar","year":"2008","unstructured":"Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD (2008) Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and Bacillus Calmette-Guerin immunotherapy in bladder cancer. Cancer Genet Cytogenet 184:1\u20138","journal-title":"Cancer Genet Cytogenet"},{"key":"1056_CR4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13547500902818246","volume":"14","author":"DK Ahirwar","year":"2009","unstructured":"Ahirwar DK, Agrahari A, Mandhani A, Mittal RD (2009a) Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 14:213\u2013218","journal-title":"Biomarkers"},{"key":"1056_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.arcmed.2008.11.006","volume":"40","author":"D Ahirwar","year":"2009","unstructured":"Ahirwar D, Mandhani A, Mittal RD (2009b) Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer. Arch Med Res 40:97\u2013102","journal-title":"Arch Med Res"},{"key":"1056_CR6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10555-006-9004-4","volume":"25","author":"RN Apte","year":"2006","unstructured":"Apte RN, Dotan S, Elkabets M et al (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25:387\u2013408","journal-title":"Cancer Metastasis Rev"},{"key":"1056_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.immunol.16.1.27","volume":"16","author":"WP Arend","year":"1998","unstructured":"Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16:27\u201355","journal-title":"Annu Rev Immunol"},{"key":"1056_CR8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000236449","volume":"101","author":"WE Aulitzky","year":"1993","unstructured":"Aulitzky WE, Huber C, Peschel C (1993) Cytokine therapy of neoplastic and inflammatory disease. Int Arch Allergy Immunol 101:221\u2013226","journal-title":"Int Arch Allergy Immunol"},{"key":"1056_CR9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539\u2013545","journal-title":"Lancet"},{"key":"1056_CR10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccr.2005.02.013","volume":"7","author":"F Balkwill","year":"2005","unstructured":"Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211\u2013217","journal-title":"Cancer Cell"},{"key":"1056_CR11","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/bjc.1998.197","volume":"77","author":"R Bedwani","year":"1998","unstructured":"Bedwani R, Renganathan E, El Kwhsky F et al (1998) Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br J Cancer 77:1186\u20131189","journal-title":"Br J Cancer"},{"key":"1056_CR100","unstructured":"Bevers RF, de Boer EC, Kurth KH, Schamhart DH (1998) BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Netw 9(2):181\u2013186"},{"key":"1056_CR12","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.urology.2005.11.032","volume":"67","author":"HK Bid","year":"2006","unstructured":"Bid HK, Manchanda PK, Mittal RD (2006) Association of interleukin-1Ra gene polymorphism in patients with bladder cancer: case control study from North India. Urology 67:1099\u20131104","journal-title":"Urology"},{"key":"1056_CR13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.gene.6363733","volume":"2","author":"J Bidwell","year":"2001","unstructured":"Bidwell J, Keen L, Gallagher G et al (2001) Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun 2:61\u201370","journal-title":"Genes Immun"},{"key":"1056_CR14","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10555-007-9084-9","volume":"26","author":"PC Black","year":"2007","unstructured":"Black PC, Dinney CP (2007) Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev 26:623\u2013634","journal-title":"Cancer Metastasis Rev"},{"key":"1056_CR15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","volume":"15","author":"U Boehm","year":"1997","unstructured":"Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to interferon-gamma. Annu Rev Immunol 15:749\u2013795","journal-title":"Annu Rev Immunol"},{"key":"1056_CR16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","volume":"170","author":"A Bohle","year":"2003","unstructured":"Bohle A, Brandau S (2003) Immune mechanisms in Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170:964\u2013969","journal-title":"J Urol"},{"key":"1056_CR17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/1043-4666(90)90013-J","volume":"2","author":"A Bohle","year":"1990","unstructured":"Bohle A, Nowc C, Ulmer AJ et al (1990) Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma. Cytokine 2:175\u2013181","journal-title":"Cytokine"},{"key":"1056_CR18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1006\/cyto.1996.0077","volume":"8","author":"F Burke","year":"1996","unstructured":"Burke F, Relf M, Negus R, Balkwill F (1996) A cytokine profile of normal and malignant ovary. Cytokine 8:578\u2013585","journal-title":"Cytokine"},{"key":"1056_CR19","first-page":"4579","volume":"20","author":"MR Cardillo","year":"2000","unstructured":"Cardillo MR, Sale P, Di Silverio F (2000) Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 20:4579\u20134583","journal-title":"Anticancer Res"},{"key":"1056_CR20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/ijc.24013","volume":"124","author":"A Castillejo","year":"2009","unstructured":"Castillejo A, Rothman N, Murta-Nascimento C et al (2009) TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer 124:608\u2013613","journal-title":"Int J Cancer"},{"key":"1056_CR21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/00005537-200205000-00008","volume":"112","author":"SW Chandler","year":"2002","unstructured":"Chandler SW, Rassekh CH, Rodman SM, Ducatman BS (2002) Immunohistochemical localization of interleukin-10 in human oral and pharyngeal carcinomas. Laryngoscope 112:808\u2013815","journal-title":"Laryngoscope"},{"key":"1056_CR22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0022-5347(01)65748-3","volume":"156","author":"JL Chin","year":"1996","unstructured":"Chin JL, Kadhim SA, Batislam E et al (1996) Mycobacterium cell wall: an alternative to intravesical Bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol 156:1189\u20131193","journal-title":"J Urol"},{"key":"1056_CR23","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.4049\/jimmunol.172.9.5467","volume":"172","author":"C Conticello","year":"2004","unstructured":"Conticello C, Pedini F, Zeuner A et al (2004) IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 172:5467\u20135477","journal-title":"J Immunol"},{"key":"1056_CR24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860\u2013867","journal-title":"Nature"},{"key":"1056_CR25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature07086","volume":"454","author":"BN Davis","year":"2008","unstructured":"Davis BN, Hilyard AC, Lagna G, Hata A (2008) SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454:56\u201361","journal-title":"Nature"},{"key":"1056_CR26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","volume":"155","author":"TM Reijke de","year":"1996","unstructured":"de Reijke TM, de Boer EC, Kurth KH, Schamhart DH (1996) Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155:477\u2013482","journal-title":"J Urol"},{"key":"1056_CR27","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.leu.2401477","volume":"13","author":"KE Visser de","year":"1999","unstructured":"de Visser KE, Kast WM (1999) Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 13:1188\u20131199","journal-title":"Leukemia"},{"issue":"2","key":"1056_CR28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.taap.2009.12.029","volume":"244","author":"C Escudero-Lourdes","year":"2010","unstructured":"Escudero-Lourdes C, Medeiros MK, C\u00e1rdenas-Gonz\u00e1lez MC, Wnek SM, Gandolfi JA (2010) Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model. Toxicol Appl Pharmacol 244(2):162\u2013173","journal-title":"Toxicol Appl Pharmacol"},{"key":"1056_CR29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/gyno.1993.1156","volume":"50","author":"D Eustace","year":"1993","unstructured":"Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E (1993) Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 50:15\u201319","journal-title":"Gynecol Oncol"},{"key":"1056_CR30","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00262-007-0339-7","volume":"56","author":"PL Ganesan","year":"2007","unstructured":"Ganesan PL, Alexander SI, Watson D, Logan GJ, Zhang GY, Alexander IE (2007) Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression. Cancer Immunol Immunother 56:1955\u20131965","journal-title":"Cancer Immunol Immunother"},{"key":"1056_CR31","first-page":"79","volume":"24","author":"M Goldman","year":"1995","unstructured":"Goldman M, Velu T (1995) Interleukin-10 and its implications for immunopathology. Adv Nephrol Necker Hosp 24:79\u201390","journal-title":"Adv Nephrol Necker Hosp"},{"key":"1056_CR32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/apmr.2002.29653","volume":"83","author":"SL Groah","year":"2002","unstructured":"Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman RF (2002) Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil 83:346\u2013351","journal-title":"Arch Phys Med Rehabil"},{"key":"1056_CR33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4161\/cbt.7.1.5134","volume":"7","author":"DA Hameed","year":"2008","unstructured":"Hameed DA, El-Metwally TH (2008) The effectiveness of retinoic acid treatment in bladder cancer: impact on recurrence, survival and TGFalpha and VEGF as end-point biomarkers. Cancer Biol Ther 7:92\u2013100","journal-title":"Cancer Biol Ther"},{"key":"1056_CR34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1001\/jama.282.11.1076","volume":"282","author":"DM Harlan","year":"1999","unstructured":"Harlan DM, Kirk AD (1999) The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? JAMA 282:1076\u20131082","journal-title":"JAMA"},{"key":"1056_CR35","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0022-5347(17)37582-1","volume":"147","author":"SJ Hawkyard","year":"1992","unstructured":"Hawkyard SJ, Jackson AM, James K, Prescott S, Smyth JF, Chisholm GD (1992) The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol 147:1399\u20131403","journal-title":"J Urol"},{"key":"1056_CR36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrc1046","volume":"3","author":"SP Hussain","year":"2003","unstructured":"Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. Nat Rev Cancer 3:276\u2013285","journal-title":"Nat Rev Cancer"},{"key":"1056_CR37","first-page":"2104","volume":"6","author":"K Inoue","year":"2000","unstructured":"Inoue K, Slaton JW, Eve BY et al (2000) Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6:2104\u20132119","journal-title":"Clin Cancer Res"},{"key":"1056_CR38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","volume":"99","author":"AM Jackson","year":"1995","unstructured":"Jackson AM, Alexandroff AB, Kelly RW et al (1995) Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99:369\u2013375","journal-title":"Clin Exp Immunol"},{"key":"1056_CR39","doi-asserted-by":"crossref","first-page":"G626","DOI":"10.1152\/ajpgi.2001.281.3.G626","volume":"281","author":"M Jaiswal","year":"2001","unstructured":"Jaiswal M, LaRusso NF, Gores GJ (2001) Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 281:G626\u2013G634","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1056_CR40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/oxfordjournals.aje.a113768","volume":"119","author":"AF Kantor","year":"1984","unstructured":"Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni JF Jr (1984) Urinary tract infection and risk of bladder cancer. Am J Epidemiol 119:510\u2013515","journal-title":"Am J Epidemiol"},{"key":"1056_CR41","first-page":"2630","volume":"54","author":"K Kawai","year":"1994","unstructured":"Kawai K, Kawamata H, Kemeyama S, Rademaker A, Oyasu R (1994) Persistence of carcinogen-altered cell population in rat urothelium which can be promoted to tumors by chronic inflammatory stimulus. Cancer Res 54:2630\u20132632","journal-title":"Cancer Res"},{"key":"1056_CR42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","volume":"134","author":"DR Kelley","year":"1985","unstructured":"Kelley DR, Ratliff TL, Catalona WJ et al (1985) Intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of Bacillus Calmette-Guerin viability on treatment results. J Urol 134:48\u201353","journal-title":"J Urol"},{"key":"1056_CR43","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.3390\/cancers3033055","volume":"3","author":"H Kitamura","year":"2011","unstructured":"Kitamura H, Tsukamoto T (2011) Immunotherapy for urothelial carcinoma: current status and perspectives. Cancers 3:3055\u20133072","journal-title":"Cancers"},{"key":"1056_CR44","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.urology.2007.12.072","volume":"71","author":"R Konwar","year":"2008","unstructured":"Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, Bid HK (2008) Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology 71:868\u2013872","journal-title":"Urology"},{"key":"1056_CR45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3727\/096504009788428442","volume":"17","author":"R Konwar","year":"2009","unstructured":"Konwar R, Chaudhary P, Kumar S, Mishra D, Chattopadhyay N, Bid HK (2009) Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women. Oncol Res 17:367\u2013372","journal-title":"Oncol Res"},{"key":"1056_CR46","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1200\/JCO.2005.01.598","volume":"23","author":"D Leibovici","year":"2005","unstructured":"Leibovici D, Grossman HB, Dinney CP et al (2005) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23:5746\u20135756","journal-title":"J Clin Oncol"},{"key":"1056_CR47","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1172\/JCI31537","volume":"117","author":"WW Lin","year":"2007","unstructured":"Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175\u20131183","journal-title":"J Clin Invest"},{"key":"1056_CR48","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/CMR.9.4.532","volume":"9","author":"DR Lucey","year":"1996","unstructured":"Lucey DR, Clerici M, Shearer GM (1996) Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9:532\u2013562","journal-title":"Clin Microbiol Rev"},{"key":"1056_CR49","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","volume":"162","author":"Y Luo","year":"1999","unstructured":"Luo Y, Chen X, Downs TM, DeWolf WC, O\u2019Donnell MA (1999) IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis Bacillus Calmette-Guerin immunotherapy. J Immunol 162:2399\u20132405","journal-title":"J Immunol"},{"key":"1056_CR50","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2249.2010.04105.x","volume":"160","author":"Y Luo","year":"2004","unstructured":"Luo Y, Han R, Evanoff DP, Chen X (2004) Interleukin-10 inhibits Mycobacterium bovis Bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol 160:359\u2013368","journal-title":"Clin Exp Immunol"},{"key":"1056_CR51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ijc.20889","volume":"115","author":"M Margalit","year":"2005","unstructured":"Margalit M, Shibolet O, Klein A et al (2005) Suppression of hepatocellular carcinoma by transplantation of ex vivo immune-modulated NKT lymphocytes. Int J Cancer 115:443\u2013449","journal-title":"Int J Cancer"},{"key":"1056_CR52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.urolonc.2006.10.002","volume":"25","author":"DS Michaud","year":"2007","unstructured":"Michaud DS (2007) Chronic inflammation and bladder cancer. Urol Oncol 25:260\u2013268","journal-title":"Urol Oncol"},{"key":"1056_CR53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0014-5793(89)80805-1","volume":"250","author":"S Miki","year":"1989","unstructured":"Miki S, Iwano M, Miki Y et al (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250:607\u2013610","journal-title":"FEBS Lett"},{"key":"1056_CR54","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.pathol.4.110807.092230","volume":"4","author":"AP Mitra","year":"2009","unstructured":"Mitra AP, Cote RJ (2009) Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 4:251\u2013285","journal-title":"Annu Rev Pathol"},{"key":"1056_CR55","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1440-1746.2006.04538.x","volume":"22","author":"RD Mittal","year":"2007","unstructured":"Mittal RD, Manchanda PK, Bid HK, Ghoshal UC (2007) Analysis of polymorphisms of tumor necrosis factor-alpha and polymorphic xenobiotic metabolizing enzymes in inflammatory bowel disease: study from northern India. J Gastroenterol Hepatol 22:920\u2013924","journal-title":"J Gastroenterol Hepatol"},{"key":"1056_CR56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.iy.11.040193.001121","volume":"11","author":"KW Moore","year":"1993","unstructured":"Moore KW, O\u2019Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165\u2013190","journal-title":"Annu Rev Immunol"},{"key":"1056_CR57","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","volume":"19","author":"KW Moore","year":"2001","unstructured":"Moore KW, de Waal Malefyt R, Coffman RL, O\u2019Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683\u2013765","journal-title":"Annu Rev Immunol"},{"key":"1056_CR58","first-page":"4581","volume":"55","author":"M Okamoto","year":"1995","unstructured":"Okamoto M, Kawamata H, Kawai K, Oyasu R (1995) Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin 6. Cancer Res 55:4581\u20134585","journal-title":"Cancer Res"},{"key":"1056_CR59","first-page":"4649","volume":"56","author":"M Okamoto","year":"1996","unstructured":"Okamoto M, Kawai K, Reznikoff CA, Oyasu R (1996) Transformation in vitro of a nontumorigenic rat urothelial cell line by hydrogen peroxide. Cancer Res 56:4649\u20134653","journal-title":"Cancer Res"},{"key":"1056_CR60","first-page":"141","volume":"57","author":"M Okamoto","year":"1997","unstructured":"Okamoto M, Lee C, Oyasu R (1997a) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:141\u2013146","journal-title":"Cancer Res"},{"key":"1056_CR61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-D","volume":"72","author":"M Okamoto","year":"1997","unstructured":"Okamoto M, Hattori K, Oyasu R (1997b) Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 72:149\u2013154","journal-title":"Int J Cancer"},{"key":"1056_CR62","first-page":"1","volume":"29","author":"AF Petit-Bertron","year":"2005","unstructured":"Petit-Bertron AF, Pedron T, Gross U et al (2005) Adherence modifies the regulation of gene expression induced by interleukin-10. Cytokine 29:1\u201312","journal-title":"Cytokine"},{"key":"1056_CR63","doi-asserted-by":"crossref","unstructured":"Pooja S, Francis A, Bid HK, Kumar S, Rajender S, Ramalingam K, Thangaraj K, Konwar R (2011) Role of ethnic variations in TNF-\u03b1 and TNF-\u03b2 polymorphisms and risk of breast cancer in India. Breast Cancer Res Treat 126(3):739\u2013747","DOI":"10.1007\/s10549-010-1175-6"},{"key":"1056_CR64","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-5347(17)42445-1","volume":"139","author":"TL Ratliff","year":"1988","unstructured":"Ratliff TL, Kavoussi LR, Catalona WJ (1988) Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 139:410\u2013414","journal-title":"J Urol"},{"key":"1056_CR65","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/cgt.2009.27","volume":"16","author":"J Reay","year":"2009","unstructured":"Reay J, Kim SH, Lockhart E, Kolls J, Robbins PD (2009) Adenoviral-mediated, intratumor gene transfer of interleukin 23 induces a therapeutic antitumor response. Cancer Gene Ther 16:776\u2013785","journal-title":"Cancer Gene Ther"},{"key":"1056_CR66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1078-1439(00)00079-X","volume":"5","author":"CA Reznikoff","year":"2000","unstructured":"Reznikoff CA, Sarkar S, Julicher KP et al (2000) Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol Oncol 5:191\u2013203","journal-title":"Urol Oncol"},{"key":"1056_CR67","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0022-5347(01)65921-4","volume":"156","author":"B Sander","year":"1996","unstructured":"Sander B, Damm O, Gustafsson B, Andersson U, Hakansson L (1996) Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical Bacillus Calmette-Guerin. J Urol 156:536\u2013541","journal-title":"J Urol"},{"issue":"Suppl 3","key":"1056_CR68","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000052388","volume":"37","author":"DH Schamhart","year":"2000","unstructured":"Schamhart DH, de Boer EC, de Reijke TM, Kurth K (2000) Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use. Eur Urol 37(Suppl 3):16\u201323","journal-title":"Eur Urol"},{"key":"1056_CR69","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1073\/pnas.90.3.863","volume":"90","author":"W Schmiegel","year":"1993","unstructured":"Schmiegel W, Roeder C, Schmielau J, Rodeck U, Kalthoff H (1993) Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci USA 90:863\u2013867","journal-title":"Proc Natl Acad Sci USA"},{"key":"1056_CR70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1475-2867-10-21","volume":"10","author":"K Schwarzer","year":"2010","unstructured":"Schwarzer K, Foerster M, Steiner T, Hermann IM, Straube E (2010) BCG strain S4-Jena: an early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis. Cancer Cell Int 10:21","journal-title":"Cancer Cell Int"},{"key":"1056_CR71","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0302-2838(03)00047-2","volume":"43","author":"M Seddighzadeh","year":"2003","unstructured":"Seddighzadeh M, Larsson P, Ulfgren AC et al (2003) Low IL-1alpha expression in bladder cancer tissue and survival. Eur Urol 43:362\u2013368","journal-title":"Eur Urol"},{"key":"1056_CR72","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-5347(17)36721-6","volume":"148","author":"T Seguchi","year":"1992","unstructured":"Seguchi T, Yokokawa K, Sugao H, Nakano E, Sonoda T, Okuyama A (1992) Interleukin-6 activity in urine and serum in patients with bladder carcinoma. J Urol 148:791\u2013794","journal-title":"J Urol"},{"key":"1056_CR73","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.2741\/3066","volume":"13","author":"G Sethi","year":"2008","unstructured":"Sethi G, Sung B, Aggarwal B (2008) TNF: a masterswitch for inflammation to cancer. Front Biosci 13:5094\u20135107","journal-title":"Front Biosci"},{"key":"1056_CR74","first-page":"1611","volume":"43","author":"A Shapiro","year":"1983","unstructured":"Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guerin and its correlation with Bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res 43:1611\u20131615","journal-title":"Cancer Res"},{"key":"1056_CR75","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/01.ju.0000164720.72732.9c","volume":"174","author":"AR Sharif-Afshar","year":"2005","unstructured":"Sharif-Afshar AR, Donohoe JM, Pope JCT, Adams MC, Brock JW III, Bhowmick NA (2005) Stromal hyperplasia in male bladders upon loss of transforming growth factor-beta signaling in fibroblasts. J Urol 174:1704\u20131707 (discussion 7)","journal-title":"J Urol"},{"key":"1056_CR76","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","volume":"14","author":"Y Shintani","year":"2007","unstructured":"Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T (2007) Intravesical instillation therapy with Bacillus Calmette-Guerin for superficial bladder cancer: study of the mechanism of Bacillus Calmette-Guerin immunotherapy. Int J Urol 14:140\u2013146","journal-title":"Int J Urol"},{"key":"1056_CR77","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nrc1208","volume":"3","author":"PM Siegel","year":"2003","unstructured":"Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3:807\u2013821","journal-title":"Nat Rev Cancer"},{"key":"1056_CR78","first-page":"161","volume":"12","author":"W Sosroseno","year":"1994","unstructured":"Sosroseno W, Herminajeng E, Goeno S (1994) The interleukin network in the immunopathogenesis of oral diseases. Asian Pac J Allergy Immunol 12:161\u2013168","journal-title":"Asian Pac J Allergy Immunol"},{"key":"1056_CR79","first-page":"4529","volume":"19","author":"NE Stavropoulos","year":"1999","unstructured":"Stavropoulos NE, Ioachim E, Pappa L, Hastazeris K, Agnantis NJ (1999) Antiproliferative activity of interferon gamma in superficial bladder cancer. Anticancer Res 19:4529\u20134533","journal-title":"Anticancer Res"},{"key":"1056_CR80","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0090-4295(96)00375-5","volume":"48","author":"P Stricker","year":"1996","unstructured":"Stricker P, Pryor K, Nicholson T et al (1996) Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 48:957\u2013961 (discussion 61\u201362)","journal-title":"Urology"},{"key":"1056_CR81","first-page":"4516","volume":"59","author":"M Suganuma","year":"1999","unstructured":"Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H (1999) Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 59:4516\u20134518","journal-title":"Cancer Res"},{"key":"1056_CR82","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0022-5347(01)61985-2","volume":"161","author":"HS Swana","year":"1999","unstructured":"Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM (1999) Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol 161:630\u2013634","journal-title":"J Urol"},{"key":"1056_CR83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1022951824806","volume":"21","author":"S Wojtowicz-Praga","year":"2003","unstructured":"Wojtowicz-Praga S (2003) Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 21:21\u201332","journal-title":"Invest New Drugs"},{"key":"1056_CR84","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.cr.7290133","volume":"12","author":"W Xu","year":"2002","unstructured":"Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311\u2013320","journal-title":"Cell Res"},{"key":"1056_CR85","first-page":"5329","volume":"52","author":"M Yamamoto","year":"1992","unstructured":"Yamamoto M, Wu HH, Momose H, Rademaker A, Oyasu R (1992) Marked enhancement of rat urinary bladder carcinogenesis by heat-killed Escherichia coli. Cancer Res 52:5329\u20135333","journal-title":"Cancer Res"},{"key":"1056_CR86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0006-2952(01)00831-0","volume":"63","author":"Y Zhang","year":"2002","unstructured":"Zhang Y, Mahendran R, Yap LL, Esuvaranathan K, Khoo HE (2002) The signalling pathway for BCG-induced interleukin-6 production in human bladder cancer cells. Biochem Pharmacol 63:273\u2013282","journal-title":"Biochem Pharmacol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-011-1056-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-011-1056-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-011-1056-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T19:14:35Z","timestamp":1686338075000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-011-1056-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,20]]},"references-count":87,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1007\/s00432-011-1056-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,20]]}}}